finance Archives

Biotech By Kate Sheridan

3 biotech trends to watch in 2022

Health Tech By Katie Palmer

Oracle to buy electronic health records giant Cerner for $28.3 billion

Health Tech By Katie Palmer

Health tech’s sky-high projections in 2021 have already been punctured

Biotech By Kate Sheridan

Biotech investor Eli Casdin on biotech’s bad December

Pharmalot By Ed Silverman

Socially responsible investor coalitions push greater access to medicines in shareholder proposals

Pharmalot By Ed Silverman

By selling bonds tied to drug access and climate goals, Teva takes pharma in a new direction

Biotech By Larry Edelman — Boston Globe

Moderna millionaires and the double-edged sword of stock market riches

Biotech By Kate Sheridan

Licensing biotech breakthroughs is a contentious, painful slog. Can the process be fixed?

Health Tech By Mario Aguilar and Matthew Herper

‘I don’t know anybody who wants their health disrupted’: Ken Frazier steps out in new venture capital role

Biotech By Hyacinth Empinado and Kate Sheridan

Watch: What’s up with tranched deals in biotech?

Biotech By Kate Sheridan

In the ‘fail fast’ world of biotech, ‘offboarding’ is just as important as onboarding

Biotech By Kate Sheridan

Graduate students launch an entrepreneurship program to bring new faces to biotech

Politics By Rachel Cohrs

Big business lobbies bitterly divided over drug pricing reform

Pharmalot By Ed Silverman

Citing competitive concerns, European Commission seeks to intervene in Illumina’s $8 billion acquisition of Grail

Pharmalot By Casey Ross

Pharmalittle: FDA scientists skeptical on boosters; moderate Democrats sink Pelosi’s drug pricing proposal

Biotech By Kate Sheridan

In another sign of RNA’s growing popularity, the cancer startup Replicate is relaunching

Biotech By Matthew Herper and Kate Sheridan

STAT+ Conversation: Which biotech venture capital funds performed best during the pandemic?

Exclusive By Kate Sheridan

Flagship, Orbimed, ARCH, Alta top list of high-performing biotech venture capital firms

close up of us dollar money flying over black

Pharmalot By Ed Silverman

Former Medivation exec charged with insider trading after buying stock ‘within minutes’ of learning of a deal

Health Tech By STAT Staff

With Amwell’s deal, the acquisition race heats up in telehealth

Health Tech By Mario Aguilar, Erin Brodwin, Katie Palmer and Casey Ross

The most intriguing health tech deals of the year (so far)

Health Tech By Erin Brodwin

Inside the ‘land grab’ for virtual-first care: how an unprecedented flurry of deals is shaping the new digital health landscape

Health Tech By Mario Aguilar

Pear Therapeutics to go public in $1.6 billion SPAC merger

Pharmalot By Ed Silverman

Planned changes at Soros’ Open Society has access-to-medicines advocacy groups on edge

Biotech By Damian Garde and Hyacinth Empinado

Most Read

At biotech venture capital firms, collecting ‘consulting fees’ from startups has become widespread

Flagship Pioneering’s Noubar Afeyan on the crazy idea behind Moderna and professional entrepreneurs

GlaxoSmithKline’s Emma Walmsley predicts a ‘landmark’ 2022 for the company

The Catholic hospital system Ascension is running a Wall Street-style private equity fund

How America’s largest Catholic hospital system is moonlighting as a private equity firm

Moderna, making billions from its vaccine, bets on a genome-editing startup

Biogen’s Aduhelm sales fall dramatically below Wall Street’s expectations

Cityblock Health raises another mega-round of funding, tipping its valuation over $5 billion

All Coverage

3 biotech trends to watch in 2022

Oracle to buy electronic health records giant Cerner for $28.3 billion

Health tech’s sky-high projections in 2021 have already been punctured

Biotech investor Eli Casdin on biotech’s bad December

Socially responsible investor coalitions push greater access to medicines in shareholder proposals

By selling bonds tied to drug access and climate goals, Teva takes pharma in a new direction

Moderna millionaires and the double-edged sword of stock market riches

Licensing biotech breakthroughs is a contentious, painful slog. Can the process be fixed?

‘I don’t know anybody who wants their health disrupted’: Ken Frazier steps out in new venture capital role

Watch: What’s up with tranched deals in biotech?

In the ‘fail fast’ world of biotech, ‘offboarding’ is just as important as onboarding

Graduate students launch an entrepreneurship program to bring new faces to biotech

Big business lobbies bitterly divided over drug pricing reform

Citing competitive concerns, European Commission seeks to intervene in Illumina’s $8 billion acquisition of Grail

Pharmalittle: FDA scientists skeptical on boosters; moderate Democrats sink Pelosi’s drug pricing proposal

In another sign of RNA’s growing popularity, the cancer startup Replicate is relaunching

STAT+ Conversation: Which biotech venture capital funds performed best during the pandemic?

Flagship, Orbimed, ARCH, Alta top list of high-performing biotech venture capital firms

Former Medivation exec charged with insider trading after buying stock ‘within minutes’ of learning of a deal

With Amwell’s deal, the acquisition race heats up in telehealth

The most intriguing health tech deals of the year (so far)

Inside the ‘land grab’ for virtual-first care: how an unprecedented flurry of deals is shaping the new digital health landscape

Pear Therapeutics to go public in $1.6 billion SPAC merger

Planned changes at Soros’ Open Society has access-to-medicines advocacy groups on edge

Watch: SPACs are all the rage, but what are they? STAT explains